Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA Presents Data on Novel Antitoxins in Development for Botulism Poisoning

Oct 03, 2011 8:01am EDT

XOMA Secures Federal Contract to Expand Its Next-Generation Human Botulism Antitoxin Portfolio

Oct 03, 2011 8:00am EDT

XOMA Announces Presentation and Webcast at Wedbush Securities 2011 Life Sciences Conference

Aug 10, 2011 4:04pm EDT

XOMA Reports Second Quarter 2011 Financial Results

Aug 04, 2011 4:02pm EDT

XOMA to Announce Second Quarter 2011 Financial Results and Host Webcast Conference Call on August 4

Jul 28, 2011 8:00am EDT

XOMA Discovers Two New Classes of Insulin Receptor-Regulating Antibodies

Jun 27, 2011 8:00am EDT

XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological Activity

Jun 08, 2011 4:15pm EDT

XOMA Appoints Paul Rubin, M.D. as Vice President and Chief Medical Officer

Jun 07, 2011 8:00am EDT

XOMA Announces Presentation and Webcast at Jefferies 2011 Global Healthcare Conference

Jun 03, 2011 8:00am EDT

XOMA Reports First Quarter 2011 Financial Results

May 05, 2011 4:05pm EDT
RSS
  • Prev
    • 1...
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • ...47
    Next
    • Email Alerts
    • RSS News Feed
    • Terms of Use

    © 2025 XOMA Royalty Corporation.  All rights reserved.

    All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

    • Follow us:
    © 2025 XOMA • Powered by GeneratePress
    Scroll back to top